Overview

Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

Status:
Not yet recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

For this protocol, the investigators plan to collect pilot data to: 1. establish the feasibility and safety of administering brexanolone to individuals with concurrent Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD).

Phase:

Phase 1

Details

Lead Sponsor:

Yale University

Collaborators:

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Sage Therapeutics

Treatments:

Brexanolone